{"id":"sotagliflozin-low-dose","safety":{"commonSideEffects":[{"rate":"8-15","effect":"Genital mycotic infections"},{"rate":"5-10","effect":"Urinary tract infections"},{"rate":"5-8","effect":"Nausea"},{"rate":"5-8","effect":"Diarrhea"},{"rate":null,"effect":"Diabetic ketoacidosis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Sotagliflozin is a dual SGLT1/SGLT2 inhibitor that works by blocking sodium-glucose cotransporters in the proximal tubule of the kidney and in the small intestine. By inhibiting SGLT2, it increases urinary glucose excretion; by inhibiting SGLT1, it reduces intestinal glucose absorption. This dual mechanism provides additional glycemic control compared to SGLT2-only inhibitors.","oneSentence":"Sotagliflozin inhibits both SGLT2 and SGLT1 transporters to reduce glucose reabsorption in the kidneys and intestines, lowering blood glucose levels.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:35:33.864Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Type 1 diabetes mellitus (in combination with insulin)"}]},"trialDetails":[{"nctId":"NCT07211802","phase":"PHASE3","title":"CKM For Safe Use of SGLT2i in Type 1 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Diego","startDate":"2026-07-01","conditions":"Type 1 Diabetes (T1D)","enrollment":52},{"nctId":"NCT02421510","phase":"PHASE3","title":"Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy","status":"COMPLETED","sponsor":"Lexicon Pharmaceuticals","startDate":"2015-05","conditions":"Type 1 Diabetes Mellitus","enrollment":782}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Sotagliflozin Low Dose","genericName":"Sotagliflozin Low Dose","companyName":"University of California, San Diego","companyId":"university-of-california-san-diego","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sotagliflozin inhibits both SGLT2 and SGLT1 transporters to reduce glucose reabsorption in the kidneys and intestines, lowering blood glucose levels. Used for Type 2 diabetes mellitus, Type 1 diabetes mellitus (in combination with insulin).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}